The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction

Launched by SARA ELADAWY · Apr 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of adding a medication called metformin to the treatment of obese patients who have heart failure with preserved ejection fraction (HFpEF). Heart failure with preserved ejection fraction means the heart can pump blood normally, but it doesn't fill with enough blood, which can cause symptoms like fatigue and shortness of breath. Researchers want to see if metformin, a drug typically used to manage blood sugar levels in diabetes, can help improve outcomes for these patients, especially since obesity and heart failure are closely linked and can lead to more serious health issues.

To participate in this trial, potential candidates should be between 40 and 74 years old, have a body mass index (BMI) of 30 or higher (which indicates obesity), and be experiencing moderate to severe heart failure symptoms. Participants will be asked to provide their written consent and will be monitored throughout the study. It’s important to note that certain individuals, such as those with different types of heart failure or specific health conditions, won't be eligible for this trial. Overall, this study aims to find out if metformin can help improve heart health in a group of patients who currently have limited treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * - Inclusion criteria:
• • Age of 40 years to 74 years.
• • HFpEF (≥ 50%)
• • Written informed consent of the subject to participate in the study.
• • New York Heart Association functional class II-IV.
• • Body mass index ≥ 30 Kg/m2
• Exclusion Criteria:
• * - Exclusion criteria:
• • Patients with heart failure with reduced ejection fraction (\< 40%)
• • Age less than 40 and more than 74
• • New York Heart Association functional class I
• • Body mass index \< 30 Kg/m2
• • Diabetic patients or prior metformin user
• • Renal impairment
• • Known allergy to metformin
• • End- stage liver disease
• • Cancer
• • Pregnancy or lactation